The oncogenic lncRNA MIR503HG suppresses cellular senescence counteracting supraphysiological androgen treatment in prostate cancer
The lncRNA MIR503HG acts as an oncogenic regulator in PCa by repressing cellular senescence. SAL-induced suppression of MIR503HG enhances the tumor-suppressive effects of AR signaling, suggesting that MIR503HG could serve as a biomarker for BAT responsiveness and as a target for combination therapies with PARP inhibitors.
Authors
- Aria Baniahmad (ORCID: https://orcid.org/0000-0003-1085-9161)
- Golnaz Atri Roozbahani
- Julia Kallenbach
- Katrin Schindler
- Mehdi Heidari Horestani
- Mahdi Rasa
Institutions
- University Hospital Schleswig-Holstein (DE)
- Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) (DE)
- Jena University Hospital (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2024-12-16
- DOI
- https://doi.org/10.1186/s13046-024-03233-2
- Citations
- 8
- Primary Topic
- Cancer-related molecular mechanisms research
- Type
- article
- Field-Weighted Citation Impact
- 2.28
Funders
- Deutscher Akademischer Austauschdienst
- Deutsche Krebshilfe
- Universitätsklinikum Jena
- Medizinische Universität Innsbruck
- Universität Innsbruck